Skip to main content
. 2010 Nov 24;5(11):e15051. doi: 10.1371/journal.pone.0015051

Table 1. Comparison of baseline demographics and clinical characteristics according to frequency of viral load testing.

Frequency of viral load testing
Characteristics Total (n = 128) Standard, n = 74 Less frequent, n = 54 P
Age, years 40.0 (33.0, 48.2) 39.7 (32.5, 48.7) 40.9 (35.1, 47.6) 0.710
Male 104 59 (80) 45 (83) 0.606
MSM 49 36 (49) 13 (24) 0.005
Distance from HIV center (>160 km) 70 30 (41) 40 (74) <0.001
Migrant worker (seafarer) 16 3 (4) 13 (24) <0.001
High school or lower education 83 44 (59) 39 (72) 0.135
Urban residence 83 47 (64) 36 (67) 0.712
Baseline CD4 count, cells/µL 276.0 (197.0, 432.5) 271.5 (187.0, 417.0) 296.5 (208.0, 457.0) 0.711
Baseline CD4 count <200 cells/µL 33 22 (30) 11 (20) 0.232
Clinical AIDS before CART 44 26 (35) 18 (33) 0.832
CART initiation year
1999–2001 48 24 (32) 24 (44) 0.166
2002–2004 80 50 (68) 30 (56)
CART failure 31 24 (32) 7 (11) 0.011
Baseline CART
NNRT-based 62 34 (46) 28 (52) 0.661
PI-based 63 37 (50) 26 (48)
Had CART change on follow-up 65 40 (54) 25 (46) 0.386
Viral load before CART, log10 copies/ml 5.3 (4.8, 5.8) 5.2 (4.7, 5.7) 5.4 (4.9, 5.8) 0.307
CD4 cell count before CART, cells/µL 108.5 (25.0, 217.5) 89.5 (26.0, 193.0) 127.0 (24.0, 233.0) 0.216
Has hepatitis C antibody 16 5 (7) 11 (20) 0.021
Years of follow-up 5.0 (3.8–6.7) 4.4 (2.6, 6.1) 5.9 (4.3, 7.6) <0.001

Standard, subjects having <50% of measurements <5 months apart. Less frequent, subjects having ≥50% of measurements >5 months apart.

Values are N (%) or median (interquartile range).

MSM, men who have sex with men; CART, combination antiretroviral therapy; NNRT, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.